Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?-Reference-Cited by-同舟云学术

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Published:2023-07-22 Issue:14 Volume:149 Page:13271-13277
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Güner Gürkan,Aktaş Burak Yasin,Başal Fatma Buğdaycı,Demirkazık Ahmet,Gürsoy Pınar,Demirci Umut,Erman Mustafa,Yumuk Perran Fulden,Şenler Filiz Çay,Çakar Burcu,Çiçin İrfan,Öztürk Akın,Coşkun Hasan Şenol,Çubukçu Erdem,Işıkdoğan Abdurrahman,Ölmez Ömer Fatih,Tatlı Ali Murat,Karaağaç Mustafa,Şakalar Teoman,Eralp Yeşim,Korkmaz Taner,Kılıçkap Saadettin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05190-3.pdf

Reference33 articles.

1. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Zalcman G (2016) Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387(10026):1415–1426. https://doi.org/10.1016/s0140-6736(16)00004-0

2. Bilgin B, Şendur MAN, Yücel Ş, Hizal M, Güner G, Akyürek N, Erol C, Akıncı MB, Dede D, Yalçın B, Kılıçkap S (2021) The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. J Cancer Res Clin Oncol 147(9):2637–2643. https://doi.org/10.1007/s00432-021-03546-1

3. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Popat S (2020) Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 38(31):3592–3603. https://doi.org/10.1200/jco.20.00505

4. Campos-Balea B, de Castro Carpeño J, Massutí B, Vicente-Baz D, Pérez Parente D, Ruiz-Gracia P, Crama L, Cobo Dols M (2020) Prognostic factors for survival in patients with metastatic lung adenocarcinoma: an analysis of the SEER database. Thoracic Cancer 11(11):3357–3364. https://doi.org/10.1111/1759-7714.13681

5. Chen G, Chen X, Zhang Y, Yan F, Fang W, Yang Y, Hong S, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Zhou N, Zhao H, Zhang L (2017) A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer. Cancer Med 6(5):953–961. https://doi.org/10.1002/cam4.1059